Last reviewed 2026-04-20 · How we verify

Lupin albuterol HFA MDI

Lupin, Inc. · Phase 3 active Small molecule Quality 0/100

Lupin albuterol HFA MDI is a Small molecule drug developed by Lupin, Inc.. It is currently in Phase 3 development.

At a glance

Generic name	Lupin albuterol HFA MDI
Sponsor	Lupin, Inc.
Modality	Small molecule
Phase	Phase 3

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Pharmacodynamic Bioequivalence of Metered Dose Inhalers of Albuterol Sulfate in Patients With Stable Mild Asthma (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Lupin albuterol HFA MDI CI brief — competitive landscape report
Lupin albuterol HFA MDI updates RSS · CI watch RSS
Lupin, Inc. portfolio CI

Frequently asked questions about Lupin albuterol HFA MDI

What is Lupin albuterol HFA MDI?

Lupin albuterol HFA MDI is a Small molecule drug developed by Lupin, Inc..

Who makes Lupin albuterol HFA MDI?

Lupin albuterol HFA MDI is developed by Lupin, Inc. (see full Lupin, Inc. pipeline at /company/lupin-inc).

What development phase is Lupin albuterol HFA MDI in?

Lupin albuterol HFA MDI is in Phase 3.

Manufacturer: Lupin, Inc. — full pipeline
Compare: Lupin albuterol HFA MDI vs similar drugs
Pricing: Lupin albuterol HFA MDI cost, discount & access